Table 2.
Characteristics of the progressive and nonprogressive MCI patients
| Total MCI (N = 92) | Progressive (N = 48) | Nonprogressive (N = 44) | p | |
|---|---|---|---|---|
| Demographic data | ||||
| Age | 72 (6.0) | 73 (6.0) | 72 (5.4) | 0.328 |
| Sex (female) | 50% (46) | 52.1% (25) | 47.7% (21) | 0.673 |
| Education | 0.549 | |||
| Illiterate | 7.3% (6) | 10.6% (5) | 2.9% (1) | |
| Primary | 59.8% (49) | 55.3% (26) | 65.7% (23) | |
| Secondary | 23.2% (19) | 23.4% (11) | 22.9% (8) | |
| University | 9.8% (8) | 10.6% (5) | 8.6% (3) | |
| Comorbidities | ||||
| Depression | 42.3% (39) | 41.6% (20) | 43.1% (19) | 0.817 |
| Hypertension | 60.8% (56) | 54.1% (26) | 68.1% (30) | 0.137 |
| Stroke | 2.1% (2) | 0% (0) | 4.5% (2) | 0.131 |
| Diabetes mellitus | 21.7% (20) | 18.7% (9) | 25% (11) | 0.437 |
| Dyslipidemia | 33.6% (31) | 29.1% (14) | 38.6% (17) | 0.304 |
| Complete blood count | ||||
| Hemoglobin (g/dL) | 13.5 (1.62) | 13.1 (1.34) | 13.7 (1.77) | 0.255 |
| Hematocrit (%) | 41.0 (5.02) | 40.3 (4.24) | 41.5 (5.50) | 0.221 |
| WBC (× 109/L) | 7.6 [6.3;10.0] | 6.7 [5.6;8.4] | 8.2 [6.4;10.7] | 0.061 |
| Platelet (× 109/L) | 216 [187;282] | 209 [159;232] | 235 [196;286] | 0.241 |
| CSF AD biomarkers | ||||
| Aβ42 (pg/mL) | 589[432;864] | 478 [374;619] | 798 [582;928] | < 0.001 |
| Ttau (pg/mL) | 333 [227;534] | 447 [259;709] | 265 [198;353] | < 0.001 |
| Ptau (pg/mL) | 64 [43;86] | 76 [49;107] | 54 [40;66] | 0.001 |
| MMSE score | 27 [25;28] | 26 [24;28] | 27 [26;29] | 0.063 |
| APOE ɛ4 | 40.2% (37) | 63% (29) | 19.5% (8) | < 0.001 |
MCI mild cognitive impairment, WBC white blood cell, CSF cerebrospinal fluid, Aβ42 amyloid beta 1–42, Ttau total tau, Ptau phosphorylated tau, MMSE Mini-Mental State Examination, APOE ɛ4 apolipoprotein E ɛ4 allele. P values were calculated by comparing groups using Student’s t-test (or Mann–Whitney U test) for quantitative variables and Pearson’s chi-square test for qualitative variables